Global and United States Hormone Refractory Breast Cancer Market Report & Forecast 2023-2028

Report ID: 1872745 | Published Date: Jan 2025 | No. of Page: 91 | Base Year: 2024 | Rating: 4.6 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Hormone Refractory Breast Cancer Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Hormone Refractory Breast Cancer Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Hormone Refractory Breast Cancer Market Size for the Year 2017-2028
        1.2.2 Global Hormone Refractory Breast Cancer Market Size for the Year 2017-2028
    1.3 Hormone Refractory Breast Cancer Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Hormone Refractory Breast Cancer in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Hormone Refractory Breast Cancer Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Hormone Refractory Breast Cancer Market Dynamics
        1.4.1 Hormone Refractory Breast Cancer Industry Trends
        1.4.2 Hormone Refractory Breast Cancer Market Drivers
        1.4.3 Hormone Refractory Breast Cancer Market Challenges
        1.4.4 Hormone Refractory Breast Cancer Market Restraints
    1.5 Study Objectives
    1.6 Years Considered
2 Hormone Refractory Breast Cancer by Type
    2.1 Hormone Refractory Breast Cancer Market Segment by Type
        2.1.1 Tumor Markers Therapy
        2.1.2 Gene Expression Therapy
        2.1.3 Gene Mutation Therapy
    2.2 Global Hormone Refractory Breast Cancer Market Size by Type (2017, 2022 & 2028)
    2.3 Global Hormone Refractory Breast Cancer Market Size by Type (2017-2028)
    2.4 United States Hormone Refractory Breast Cancer Market Size by Type (2017, 2022 & 2028)
    2.5 United States Hormone Refractory Breast Cancer Market Size by Type (2017-2028)
3 Hormone Refractory Breast Cancer by Application
    3.1 Hormone Refractory Breast Cancer Market Segment by Application
        3.1.1 Scientific Research and Production
        3.1.2 Biological Science and Technology
        3.1.3 Medical Technology
        3.1.4 Medical Apparatus and Instruments
    3.2 Global Hormone Refractory Breast Cancer Market Size by Application (2017, 2022 & 2028)
    3.3 Global Hormone Refractory Breast Cancer Market Size by Application (2017-2028)
    3.4 United States Hormone Refractory Breast Cancer Market Size by Application (2017, 2022 & 2028)
    3.5 United States Hormone Refractory Breast Cancer Market Size by Application (2017-2028)
4 Global Hormone Refractory Breast Cancer Competitor Landscape by Company
    4.1 Global Hormone Refractory Breast Cancer Market Size by Company
        4.1.1 Top Global Hormone Refractory Breast Cancer Companies Ranked by Revenue (2021)
        4.1.2 Global Hormone Refractory Breast Cancer Revenue by Player (2017-2022)
    4.2 Global Hormone Refractory Breast Cancer Concentration Ratio (CR)
        4.2.1 Hormone Refractory Breast Cancer Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Hormone Refractory Breast Cancer in 2021
        4.2.3 Global Hormone Refractory Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Hormone Refractory Breast Cancer Headquarters, Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Hormone Refractory Breast Cancer Headquarters and Area Served
        4.3.2 Global Hormone Refractory Breast Cancer Companies Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Hormone Refractory Breast Cancer Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Hormone Refractory Breast Cancer Market Size by Company
        4.5.1 Top Hormone Refractory Breast Cancer Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Hormone Refractory Breast Cancer Revenue by Players (2020, 2021 & 2022)
5 Global Hormone Refractory Breast Cancer Market Size by Region
    5.1 Global Hormone Refractory Breast Cancer Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Hormone Refractory Breast Cancer Market Size by Region (2017-2028)
        5.2.1 Global Hormone Refractory Breast Cancer Market Size by Region: 2017-2022
        5.2.2 Global Hormone Refractory Breast Cancer Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Hormone Refractory Breast Cancer Market Size YoY Growth 2017-2028
        6.1.2 North America Hormone Refractory Breast Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Hormone Refractory Breast Cancer Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Hormone Refractory Breast Cancer Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe Hormone Refractory Breast Cancer Market Size YoY Growth 2017-2028
        6.3.2 Europe Hormone Refractory Breast Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Hormone Refractory Breast Cancer Market Size YoY Growth 2017-2028
        6.4.2 Latin America Hormone Refractory Breast Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Hormone Refractory Breast Cancer Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Hormone Refractory Breast Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 U.A.E
7 Company Profiles
    7.1 AstraZeneca
        7.1.1 AstraZeneca Company Details
        7.1.2 AstraZeneca Business Overview
        7.1.3 AstraZeneca Hormone Refractory Breast Cancer Introduction
        7.1.4 AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        7.1.5 AstraZeneca Recent Development
    7.2 AmpliMed Corporation
        7.2.1 AmpliMed Corporation Company Details
        7.2.2 AmpliMed Corporation Business Overview
        7.2.3 AmpliMed Corporation Hormone Refractory Breast Cancer Introduction
        7.2.4 AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        7.2.5 AmpliMed Corporation Recent Development
    7.3 Roche
        7.3.1 Roche Company Details
        7.3.2 Roche Business Overview
        7.3.3 Roche Hormone Refractory Breast Cancer Introduction
        7.3.4 Roche Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        7.3.5 Roche Recent Development
    7.4 Bluefish Pharmaceuticals AB
        7.4.1 Bluefish Pharmaceuticals AB Company Details
        7.4.2 Bluefish Pharmaceuticals AB Business Overview
        7.4.3 Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Introduction
        7.4.4 Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        7.4.5 Bluefish Pharmaceuticals AB Recent Development
    7.5 NeoCorp
        7.5.1 NeoCorp Company Details
        7.5.2 NeoCorp Business Overview
        7.5.3 NeoCorp Hormone Refractory Breast Cancer Introduction
        7.5.4 NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        7.5.5 NeoCorp Recent Development
    7.6 Sanofi Genzyme
        7.6.1 Sanofi Genzyme Company Details
        7.6.2 Sanofi Genzyme Business Overview
        7.6.3 Sanofi Genzyme Hormone Refractory Breast Cancer Introduction
        7.6.4 Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        7.6.5 Sanofi Genzyme Recent Development
    7.7 Neopharm
        7.7.1 Neopharm Company Details
        7.7.2 Neopharm Business Overview
        7.7.3 Neopharm Hormone Refractory Breast Cancer Introduction
        7.7.4 Neopharm Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        7.7.5 Neopharm Recent Development
    7.8 Boehringer Ingelheim GmbH
        7.8.1 Boehringer Ingelheim GmbH Company Details
        7.8.2 Boehringer Ingelheim GmbH Business Overview
        7.8.3 Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Introduction
        7.8.4 Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        7.8.5 Boehringer Ingelheim GmbH Recent Development
8 Research Findings and Conclusion
9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Hormone Refractory Breast Cancer Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Hormone Refractory Breast Cancer Market Trends
    Table 3. Hormone Refractory Breast Cancer Market Drivers
    Table 4. Hormone Refractory Breast Cancer Market Challenges
    Table 5. Hormone Refractory Breast Cancer Market Restraints
    Table 6. Global Hormone Refractory Breast Cancer Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Hormone Refractory Breast Cancer Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Hormone Refractory Breast Cancer Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Hormone Refractory Breast Cancer Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Hormone Refractory Breast Cancer Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Hormone Refractory Breast Cancer Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Hormone Refractory Breast Cancer Revenue Share by Player, 2017-2022
    Table 13. Global Hormone Refractory Breast Cancer Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Hormone Refractory Breast Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Breast Cancer as of 2021)
    Table 15. Top Players of Hormone Refractory Breast Cancer in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Hormone Refractory Breast Cancer Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Hormone Refractory Breast Cancer Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Hormone Refractory Breast Cancer Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Hormone Refractory Breast Cancer Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Hormone Refractory Breast Cancer Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Hormone Refractory Breast Cancer Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Hormone Refractory Breast Cancer Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Hormone Refractory Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Hormone Refractory Breast Cancer Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Hormone Refractory Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Hormone Refractory Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Hormone Refractory Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. AstraZeneca Company Details
    Table 31. AstraZeneca Business Overview
    Table 32. AstraZeneca Hormone Refractory Breast Cancer Product
    Table 33. AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 34. AstraZeneca Recent Development
    Table 35. AmpliMed Corporation Company Details
    Table 36. AmpliMed Corporation Business Overview
    Table 37. AmpliMed Corporation Hormone Refractory Breast Cancer Product
    Table 38. AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 39. AmpliMed Corporation Recent Development
    Table 40. Roche Company Details
    Table 41. Roche Business Overview
    Table 42. Roche Hormone Refractory Breast Cancer Product
    Table 43. Roche Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 44. Roche Recent Development
    Table 45. Bluefish Pharmaceuticals AB Company Details
    Table 46. Bluefish Pharmaceuticals AB Business Overview
    Table 47. Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Product
    Table 48. Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 49. Bluefish Pharmaceuticals AB Recent Development
    Table 50. NeoCorp Company Details
    Table 51. NeoCorp Business Overview
    Table 52. NeoCorp Hormone Refractory Breast Cancer Product
    Table 53. NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 54. NeoCorp Recent Development
    Table 55. Sanofi Genzyme Company Details
    Table 56. Sanofi Genzyme Business Overview
    Table 57. Sanofi Genzyme Hormone Refractory Breast Cancer Product
    Table 58. Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 59. Sanofi Genzyme Recent Development
    Table 60. Neopharm Company Details
    Table 61. Neopharm Business Overview
    Table 62. Neopharm Hormone Refractory Breast Cancer Product
    Table 63. Neopharm Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 64. Neopharm Recent Development
    Table 65. Boehringer Ingelheim GmbH Company Details
    Table 66. Boehringer Ingelheim GmbH Business Overview
    Table 67. Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Product
    Table 68. Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 69. Boehringer Ingelheim GmbH Recent Development
    Table 70. Research Programs/Design for This Report
    Table 71. Key Data Information from Secondary Sources
    Table 72. Key Data Information from Primary Sources
List of Figures
    Figure 1. Hormone Refractory Breast Cancer Product Picture
    Figure 2. Global Hormone Refractory Breast Cancer Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Hormone Refractory Breast Cancer Market Size 2017-2028 (US$ Million)
    Figure 4. United States Hormone Refractory Breast Cancer Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Hormone Refractory Breast Cancer Market Size 2017-2028 (US$ Million)
    Figure 6. United States Hormone Refractory Breast Cancer Market Share in Global 2017-2028
    Figure 7. Hormone Refractory Breast Cancer Report Years Considered
    Figure 8. Product Picture of Tumor Markers Therapy
    Figure 9. Product Picture of Gene Expression Therapy
    Figure 10. Product Picture of Gene Mutation Therapy
    Figure 11. Global Hormone Refractory Breast Cancer Market Share by Type in 2022 & 2028
    Figure 12. Global Hormone Refractory Breast Cancer Market Size by Type (2017-2028) & (US$ Million)
    Figure 13. Global Hormone Refractory Breast Cancer Market Share by Type (2017-2028)
    Figure 14. United States Hormone Refractory Breast Cancer Market Share by Type in 2022 & 2028
    Figure 15. United States Hormone Refractory Breast Cancer Market Size by Type (2017-2028) & (US$ Million)
    Figure 16. United States Hormone Refractory Breast Cancer Market Share by Type (2017-2028)
    Figure 17. Product Picture of Scientific Research and Production
    Figure 18. Product Picture of Biological Science and Technology
    Figure 19. Product Picture of Medical Technology
    Figure 20. Product Picture of Medical Apparatus and Instruments
    Figure 21. Global Hormone Refractory Breast Cancer Market Share by Application in 2022 & 2028
    Figure 22. Global Hormone Refractory Breast Cancer Market Size by Application (2017-2028) & (US$ Million)
    Figure 23. Global Hormone Refractory Breast Cancer Market Share by Application (2017-2028)
    Figure 24. United States Hormone Refractory Breast Cancer Market Share by Application in 2022 & 2028
    Figure 25. United States Hormone Refractory Breast Cancer Market Size by Application (2017-2028) & (US$ Million)
    Figure 26. United States Hormone Refractory Breast Cancer Market Share by Application (2017-2028)
    Figure 27. North America Hormone Refractory Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 28. U.S. Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. Canada Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Europe Hormone Refractory Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 31. Germany Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. France Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. U.K. Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Italy Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Russia Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Asia-Pacific Hormone Refractory Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 37. China Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. Japan Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. South Korea Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. India Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Australia Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Taiwan Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Indonesia Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Thailand Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Malaysia Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Philippines Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Latin America Hormone Refractory Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 48. Mexico Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Brazil Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Argentina Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Middle East & Africa Hormone Refractory Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 52. Turkey Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Saudi Arabia Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. U.A.E Hormone Refractory Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. AstraZeneca Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 56. AmpliMed Corporation Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 57. Roche Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 58. Bluefish Pharmaceuticals AB Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 59. NeoCorp Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 60. Sanofi Genzyme Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 61. Neopharm Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 62. Boehringer Ingelheim GmbH Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AstraZeneca
AmpliMed Corporation
Roche
Bluefish Pharmaceuticals AB
NeoCorp
Sanofi Genzyme
Neopharm
Boehringer Ingelheim GmbH
Frequently Asked Questions
Hormone Refractory Breast Cancer report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Hormone Refractory Breast Cancer report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Hormone Refractory Breast Cancer report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports